Wei Tao
- Biomaterials top 0.02%
- Nanoparticle-Based Drug Delivery 58
- Biomedical Engineering top 0.02%
- Nanoplatforms for cancer theranostics 101
- Graphene and Nanomaterials Applications 21
- Pharmaceutical Science top 0.2%
- Materials Chemistry top 0.2%
- Advanced Nanomaterials in Catalysis 23
- MXene and MAX Phase Materials 14
- Molecular Biology top 0.5%
- RNA Interference and Gene Delivery 65
- Advanced biosensing and bioanalysis techniques 44
-
- Immunotherapy and Immune Responses 14
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Wei Tao
266 papers receiving 25.9k citations
Hit Papers
Peers
Comparison fields: 5 of 179
- Biomaterials 7.1k
- Biomedical Engineering 12.9k
- Pharmaceutical Science 1.1k
- Materials Chemistry 7.8k
- Molecular Biology 9.3k
Countries citing papers authored by Wei Tao
This map shows the geographic impact of Wei Tao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Tao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Tao more than expected).
Fields of papers citing papers by Wei Tao
This network shows the impact of papers produced by Wei Tao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Tao. The network helps show where Wei Tao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Wei Tao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 6 | |
| 3 | 2025 | 7 | |
| 4 | 2025 | 3 | |
| 5 | 2024 | 3 | |
| 6 | 2024 | 7 | |
| 7 | 2024 | 5 | |
| 8 | 2024 | 35 | |
| 9 | 2023 | 27 | |
| 10 | 2023 | 44 | |
| 11 | 2023 | 98 | |
| 12 | Prediction of Acute Kidney Injury by Fibroblast Growth Factor 23 (FGF-23) in Adult Patients, A Meta-analysis Study. | 2023 | 1 |
| 13 | 2022 | 42 | |
| 14 | 2020 | 122 | |
| 15 | 2020 | 139 | |
| 16 | 2019 | 115 | |
| 17 | 2018 | 194 | |
| 18 | 2018 | 183 | |
| 19 | 2017 | 181 | |
| 20 | 2017 | 97 |
About Wei Tao
Wei Tao is a scholar working on Biomaterials, Biomedical Engineering, Pharmaceutical Science, Molecular Biology and Materials Chemistry, having authored 273 papers that have together received 26.1k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (101 papers), RNA Interference and Gene Delivery (65 papers), Nanoparticle-Based Drug Delivery (58 papers), Advanced biosensing and bioanalysis techniques (44 papers), Advanced Nanomaterials in Catalysis (23 papers), Graphene and Nanomaterials Applications (21 papers), MXene and MAX Phase Materials (14 papers) and Immunotherapy and Immune Responses (14 papers). The work is most often cited by research in Biomaterials (7.1k citations), Biomedical Engineering (12.9k citations), Pharmaceutical Science (1.1k citations), Materials Chemistry (7.8k citations) and Molecular Biology (9.3k citations). Wei Tao has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Na Kong, Omid C. Farokhzad, Xiaoyuan Ji, Jinjun Shi, Lin Mei, Jiang Ouyang, Nitin Joshi, Xiaowei Zeng, Han Zhang and Dan Peer. Their work appears in journals such as Advanced Materials, Advanced Science, Matter, Nano Letters and ACS Nano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.